Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Judiciary Committee Plans Hearings On Reimportation, "BioShield"

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Hatch asks FDA's Crawford and Troy to be ready to testify on reimportation. Bioterrorism bill includes intellectual property provisions.

You may also be interested in...



Senate Judiciary Importation Hearing

The Senate Judiciary Committee will hold a hearing on drug importation July 14

Senate Judiciary Importation Hearing

The Senate Judiciary Committee will hold a hearing on drug importation July 14

"Wild Card" Patent Extensions Part Of Second-Round Biodefense Legislation

Sens. Lieberman (D-Conn.) and Hatch (R-Utah) plan to introduce BioShield II legislation to provide intellectual property and tax incentives to induce companies to enter biodefense industry. Firms would also need greater liability protection, Lieberman counsel Chuck Ludlam says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel